US Pharma MarketingBeyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP
By Tatiana Nanda, VP, Technical Development and Analytical Services, SK pharmteco; Christopher Nieder, Senior Director, Head of Technical Development, SK pharmteco; Mardhani Aparajithan, Direct Rigid adenoviral platforms can derail GMP progress. Learn how adaptive, adenovirus-specific strategies reduce risk from development to scale.
Rigid adenoviral platforms can derail GMP progress. Learn how adaptive, adenovirus-specific strategies reduce risk from development to scale.
Source: FierceBiotech